The clinical response of an infant or child with AOME represents the principal indicator of therapeutic success or failure of an antimicrobial regimen. Despite the fact that as many as 20 to 25% of patients with AOME have beta-lactamase-producing organisms in middle ear fluid cultures, some of these patients will respond favorably to amoxicillin therapy. At present amoxicillin, erythromycin plus sulfanamide, cefaclor or amoxicillin plus clavunate is preferred for initial treatment of AOME. At completion of antibiotic therapy, approximately 60% of patients have middle ear fluid present on examination; the effusion persists in approximately 40% at 1 month, in 20% at 2 months and in 5 to 10% at 3 months posttherapy. The physician must identify those with persistent effusion and decide which mode of management is best suited for each of those patients. This decision can often be accomplished in consultation with an otolaryngologist.
|Original language||English (US)|
|Number of pages||4|
|Journal||Pediatric Infectious Disease Journal|
|Publication status||Published - 1988|
ASJC Scopus subject areas
- Microbiology (medical)
- Pediatrics, Perinatology, and Child Health